According to a report, “Vaginitis Therapeutics Market Size, Share, & Trends Analysis Report By Product (Anti-fungal, Hormone, Anti-bacterial), By Type (OTC, Prescription), By Region (APAC, MEA, North America), And Segment Forecasts, 2018 – 2025”, published by Grand View Research, Inc., The global vaginitis therapeutics market size is expected to reach USD 4.21 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to expand at a CAGR of 8.4% during the forecast period. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.
Key Takeaways from the report:
-
Anti-bacterial segment led the market in 2017 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease
-
Hormone is expected to witness lucrative growth with a CAGR of 9.1% over the forecast period due to the presence of pipeline products and rising adoption of products
-
Prescription type held the largest market share in 2017, in terms of revenue. The segment was valued at USD 1.14 billion owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis
-
Over the counter is expected to be the fastest-growing type in the coming years with a CAGR of 8.7% due to increasing number of FDA approvals for the treatment of mild vaginitis
-
North America is estimated to be the largest regional market. It was the dominant region in 2017, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis
-
Asia Pacific is expected to be the fastest-growing region registering a lucrative CAGR over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.
-
Key players in the vaginitis therapeutics market are Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; and Mission Pharmacal Company
-
Most of these companies focus on strategic initiatives, such as collaborations, M&A, and product portfolio expansion. For instance, in October 2017, Lupin Pharmaceuticals acquired Symbiomix Therapeutics to expand its product portfolio.
Browse More Reports in Pharmaceuticals Industry:
- Superdisintegrants Market – Geriatric and a pediatric population who have difficulty in swallowing tablet/capsules and development of new superdisintegrants for the pharmaceutical industry is driving Superdisintegrants market growth
- Pneumonia Therapeutics Market – Consistent increase in funding opportunities in research for the development of new products is anticipated to broaden the scope for pneumonia therapeutics market growth over the coming years
Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.
Grand View Research has segmented the global vaginitis therapeutics market on the basis of product, type, and region:
Vaginitis Therapeutics Product Outlook (Revenue, USD Million, 2014 – 2025)
-
Anti-fungal
-
Anti-bacterial
-
Hormone
Vaginitis Therapeutics Type Outlook (Revenue, USD Million, 2014 – 2025)
-
Over-The-Counter (OTC)
-
Prescription (Rx)
Vaginitis Therapeutics Regional Outlook (Revenue, USD Million, 2014 – 2025)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
Germany
-
U.K.
-
-
Asia Pacific
-
Japan
-
China
-
-
Latin America
-
Brazil
-
Mexico
-
-
MEA
-
South Africa
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grad View Research, Inc.
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/vaginitis-therapeutics-market